Berberine Nanosuspension Enhances Hypoglycemic Efficacy on Streptozotocin Induced Diabetic C57BL/6 Mice

Table 1

Changes induced by Ber-NS in biochemical parameter on diabetic C57BL/6 mice.

Group	Dose (mg/kg)	Mice		Body weight (g)		FBG (mmol/L)	TC (mmol/L)	TG (mmol/L)
		Initial	Final	Initial	Final
Nor	—	10	10	30.1 ± 1.0	31.9 ± 0.7	5.88 ± 0.53	2.39 ± 0.09	0.88 ± 0.10
Con	—	10	10	27.9 ± 1.2	30.7 ± 0.8	8.08 ± 0.85^∗∗∗	3.34 ± 0.21^∗∗∗	1.10 ± 0.12^∗∗
Met	300	10	10	28.6 ± 1.8	33.3 ± 3.6	6.92 ± 0.59^#	3.13 ± 0.36	0.99 ± 0.16
Ber	50	10	9	28.7 ± 1.6	29.3 ± 3.5	6.81 ± 0.63^#	2.97 ± 0.70	0.94 ± 0.18
BN	50	10	10	28.6 ± 1.7	32.1 ± 3.4	6.05 ± 0.45^###,Δ	2.72 ± 0.64^#	0.97 ± 0.21

Eight weeks after Ber-NS treatment, biochemical parameter of the age-matched normal control group (Nor), STZ induced diabetic group (Con), Metformin treated diabetic group (Met), bulk Ber treated diabetic group (Ber), and Ber-NS treated diabetic group (BN). Data are presented as mean ± SD from 10 animals ( = 10) for each group. < 0.05, < 0.01, < 0.001 versus Nor; < 0.05, < 0.01, < 0.001 versus Con; < 0.05 versus bulk Ber.